Unknown

Dataset Information

0

Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.


ABSTRACT: Phase III noninferiority trial examining efficacy and safety of converting stable renal transplant recipients from twice-daily tacrolimus to a novel extended-release once-daily tacrolimus formulation (LCPT) with a controlled agglomeration technology. Controls maintained tacrolimus twice daily. The primary efficacy endpoint was proportion of patients with efficacy failures (death, graft failure, locally read biopsy-proven acute rejection [BPAR], or loss to follow-up) within 12 months. Starting LCPT dose was 30% lower (15% for blacks) than preconversion tacrolimus dose; target trough levels were 4-15 ng/mL. A total of 326 patients were randomized; the mITT population (n = 162 each group) was similar demographically in the two groups. Mean daily dose of LCPT was significantly (p < 0.0001) lower than preconversion tacrolimus dose at each visit; mean trough levels between groups were similar. There were four efficacy failures in each group; safety outcomes were similar between groups. Frequency of premature study drug discontinuation was LCPT: 12% versus tacrolimus twice daily: 5% (p = 0.028). LCPT demonstrated noninferiority to tacrolimus twice daily in efficacy failure rates. LCPT may offer a safe and effective alternative for converting patients to a once-daily formulation. Compared to currently available tacrolimus formulation, LCPT requires lower doses to achieve target trough levels.

SUBMITTER: Bunnapradist S 

PROVIDER: S-EPMC3613750 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial.

Bunnapradist S S   Ciechanowski K K   West-Thielke P P   Mulgaonkar S S   Rostaing L L   Vasudev B B   Budde K K  

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20121221 3


Phase III noninferiority trial examining efficacy and safety of converting stable renal transplant recipients from twice-daily tacrolimus to a novel extended-release once-daily tacrolimus formulation (LCPT) with a controlled agglomeration technology. Controls maintained tacrolimus twice daily. The primary efficacy endpoint was proportion of patients with efficacy failures (death, graft failure, locally read biopsy-proven acute rejection [BPAR], or loss to follow-up) within 12 months. Starting LC  ...[more]

Similar Datasets

| S-EPMC3723088 | biostudies-literature
| S-EPMC6899533 | biostudies-literature
| S-EPMC4497360 | biostudies-literature
| S-EPMC5318624 | biostudies-literature
| S-EPMC9203451 | biostudies-literature
| S-EPMC6728630 | biostudies-literature
| S-EPMC4108821 | biostudies-literature
| S-EPMC6032903 | biostudies-literature
| S-EPMC8056872 | biostudies-literature
| S-EPMC4730664 | biostudies-literature